DeepLook AI Imaging Provides A Deeper Look At Dense Breast

DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.

Traditional Method vs DL Precise
(DeepLook Medical)

Women at higher risk of getting breast cancer may now have a better chance of catching tumors early. That’s because an AI-powered software tool that enhances breast screenings, especially in dense tissue, is now available at more hospitals across the country.

DeepLook Medical recently announced that several hospital systems across the US, including the Mayo Clinic, the Cleveland Clinic, AdventHealth, and Geisinger have adopted its flagship AI platform, DL Precise, which improves detection of lesions, especially in women with dense breast.

What makes dense tissue tricky is that it appears as the same white color on mammograms as cancer, which is why 50% of cancers can be missed using traditional mammograms.

Marissa Fayer, CEO of DeepLook Medical, told Medtech Insight, DL Precise offers clinicians an enhanced view of screenings by adding color to the gray images.

This is especially beneficial, Fayer said, for women with density as it provides contrast to the “white on white,” making lesions easier to spot.

Breast density, according to the American Cancer Society, does not refer to the size or firmness of the breast, but rather how much fibrous and glandular tissue is in the breast compared to fat tissue.

More than 45% of women worldwide — and more than half of women in the US older than 40 — have dense tissue, putting them at four to six times the risk of developing breast cancer compared to women with fatty breasts.

“We’re not making decisions. We’re not making recommendations. We’re augmenting what is already there with our technology. It’s as simple as that.”

Marissa Fayer

DeepLook’s FDA-cleared AI tool, Fayer explained, is like “a magnifying glass” for radiologists that overlays existing imaging systems using proprietary shape-recognition AI.

As Fayer noted, the on-demand DL Precise platform integrates directly into existing workstations, making it easier for radiologists to access it if they feel they need a deeper look.

“We’re the only one embedded into the workflow and happening live — no post-processing,” Fayer said. “We’re not making decisions. We’re not making recommendations. We’re augmenting what is already there with our technology. It’s as simple as that.”

In other words, DL Precise provides radiologists with a tool to help them do their job, not with one to replace their clinical judgement.

Marissa Fayer

Using DL Precise is user-friendly, Fayer said, requiring no additional screens, tools, or certifications and is only displayed when the clinician wishes to access it.

Fayer cited preliminary data on DL Precise from its use at a hospital in New York in which it was associated with a 12% improvement in recalls or callbacks, which is when patients are called back for further testing.

Low callback rates often result in missed cancers whereas high callback rates can lead to unnecessary supplemental imaging and biopsies.

The American College of Radiology and the FDA have established national standards for callback rates with the target rate between 8% and 9%. The current national acceptable range is 5% to 12%.

The commercial adoption of the AI platform comes at a good time, not just for DeepLook Medical but for women with dense breast as awareness about density continues to grow.

Last year, the FDA issued a final rule requiring providers inform patients about density on routine mammogram reports.

Recent data from clinical studies has shown that screenings alone are just not good enough for women with dense breasts. But data is also showing that AI tools, such as DL Precise, can aid clinicians in catching tumors in women with density much earlier. And as with all cancers, early detection is vital.

The commercial adoption of DL Precise, Fayer said, points not only to the growing demand and need for enhanced imaging, especially for dense tissue, but to the critical role AI can play in improving women’s health.

Fayer also noted plans to expand the platform outside the US.

“We’re seeing firsthand how intelligent imaging can immediately enhance clinical decision-making, reduce variability, and bring clarity to some of the most complex cases, especially in dense tissue where traditional tools often fall short,” she said.

More from AI

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

ForSight Sets Its Sights On Automating Delicate Eye Procedures

 
• By 

ForSight Robotics is developing a robotic platform to automate cataract and other eye surgeries, aiming to ease surgeon strain and expand access. Backed by $200m in total funding, it's targeting a first human surgery using Oryom by year-end and is in discussions with US FDA.

More from Policy & Regulation

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By 

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

FDA ‘Regulatory Accelerator’ Aims To Speed Digital Health Development

 
• By 

The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.

From ‘Work Harder’ to ‘Phenomenal People’: Makary’s FDA About-Face

 

In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.